219 related articles for article (PubMed ID: 35122151)
1. Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.
Tian W; Sun L; Zhang Q; Zhao J; Guo Y; Zhong W; Liu L; Meirelles K; Tang S; Zhang J; Huang Y; Yin Y; Zhang N; Zhao Z; Li Q; Wu N; Fang P; Chang F; Wu Z
Mol Genet Genomics; 2022 Mar; 297(2):387-396. PubMed ID: 35122151
[TBL] [Abstract][Full Text] [Related]
2. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
3. Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth.
Frisk S; Taylan F; Blaszczyk I; Nennesmo I; Annerén G; Herm B; Stattin EL; Zachariadis V; Lindstrand A; Tesi B; Laurell T; Nordgren A
Clin Genet; 2019 Aug; 96(2):118-125. PubMed ID: 30919936
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
5. Activating PIK3CA somatic mutation in congenital unilateral isolated muscle overgrowth of the upper extremity.
Castiglioni C; Bertini E; Orellana P; Villarroel C; Las Heras F; Hinzpeter D; Paolinelli P; Bevilacqua JA; Alvarez K
Am J Med Genet A; 2014 Sep; 164A(9):2365-9. PubMed ID: 24975390
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutations in lipomatosis of nerve with or without nerve territory overgrowth.
Blackburn PR; Milosevic D; Marek T; Folpe AL; Howe BM; Spinner RJ; Carter JM
Mod Pathol; 2020 Mar; 33(3):420-430. PubMed ID: 31481664
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
[TBL] [Abstract][Full Text] [Related]
9. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA activating mutations in facial infiltrating lipomatosis.
Maclellan RA; Luks VL; Vivero MP; Mulliken JB; Zurakowski D; Padwa BL; Warman ML; Greene AK; Kurek KC
Plast Reconstr Surg; 2014 Jan; 133(1):12e-19e. PubMed ID: 24374682
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing.
Kuentz P; St-Onge J; Duffourd Y; Courcet JB; Carmignac V; Jouan T; Sorlin A; Abasq-Thomas C; Albuisson J; Amiel J; Amram D; Arpin S; Attie-Bitach T; Bahi-Buisson N; Barbarot S; Baujat G; Bessis D; Boccara O; Bonnière M; Boute O; Bursztejn AC; Chiaverini C; Cormier-Daire V; Coubes C; Delobel B; Edery P; Chehadeh SE; Francannet C; Geneviève D; Goldenberg A; Haye D; Isidor B; Jacquemont ML; Khau Van Kien P; Lacombe D; Martin L; Martinovic J; Maruani A; Mathieu-Dramard M; Mazereeuw-Hautier J; Michot C; Mignot C; Miquel J; Morice-Picard F; Petit F; Phan A; Rossi M; Touraine R; Verloes A; Vincent M; Vincent-Delorme C; Whalen S; Willems M; Marle N; Lehalle D; Thevenon J; Thauvin-Robinet C; Hadj-Rabia S; Faivre L; Vabres P; Rivière JB
Genet Med; 2017 Sep; 19(9):989-997. PubMed ID: 28151489
[TBL] [Abstract][Full Text] [Related]
13. Upper limb muscle overgrowth with hypoplasia of the index finger: a new over-growth syndrome caused by the somatic PIK3CA mutation c.3140A>G.
Al-Qattan MM; Hadadi A; Al-Thunayan AM; Eldali AA; AlBalwi MA
BMC Med Genet; 2018 Sep; 19(1):158. PubMed ID: 30180809
[TBL] [Abstract][Full Text] [Related]
14. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
[TBL] [Abstract][Full Text] [Related]
15. Utility of clinical high-depth next generation sequencing for somatic variant detection in the PIK3CA-related overgrowth spectrum.
Hucthagowder V; Shenoy A; Corliss M; Vigh-Conrad KA; Storer C; Grange DK; Cottrell CE
Clin Genet; 2017 Jan; 91(1):79-85. PubMed ID: 27307077
[TBL] [Abstract][Full Text] [Related]
16. Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum.
Chen H; Gao W; Liu H; Sun B; Hua C; Lin X
Ann Plast Surg; 2023 May; 90(5S Suppl 2):S209-S215. PubMed ID: 36729078
[TBL] [Abstract][Full Text] [Related]
17.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
18. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
19. Clinical pitfalls in the diagnosis of segmental overgrowth syndromes: a child with the c.2740G > A mutation in PIK3CA gene.
Maguolo A; Antoniazzi F; Spano A; Fiorini E; Gaudino R; Mauro M; Cantalupo G; Biban P; Maitz S; Cavarzere P
Ital J Pediatr; 2018 Sep; 44(1):110. PubMed ID: 30231930
[TBL] [Abstract][Full Text] [Related]
20. Identification and Characterization of a Novel Constitutional PIK3CA Mutation in a Child Lacking the Typical Segmental Overgrowth of "PIK3CA-Related Overgrowth Spectrum".
Di Donato N; Rump A; Mirzaa GM; Alcantara D; Oliver A; Schrock E; Dobyns WB; O'Driscoll M
Hum Mutat; 2016 Mar; 37(3):242-5. PubMed ID: 26593112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
